Literature DB >> 2793671

Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia.

P C Engstrom1, B A Holm, S Matalon.   

Abstract

Rabbits exposed to hyperoxia develop surfactant deficiency, abnormal lung mechanics, and increased permeability to solute. We investigated whether replenishment of depleted alveolar surfactant by the intratracheal instillation of calf lung surfactant extract (CLSE) would mitigate the increase in alveolar permeability to solute. Twenty-eight rabbits were exposed to 100% O2 for 72 h and received intratracheal instillations of 125 mg CLSE (approximately 170 mumol dipalmitoyl phosphatidylcholine) at 24 and 48 h. The interlobar and intralobar distribution of CLSE was quantified by adding [14C]dipalmitoyl phosphatidylcholine liposes into the instillate and measuring the levels of activity in lung tissue. CLSE was nonuniformly distributed in the different lung lobes, the right lower lobe receiving more CLSE than the rest. Alveolar epithelial permeability to solute was assessed by instilling 10 ml isotonic saline, which contained a trace amount of [57Co]cyanocobalamin, in the right lower lobe and measuring the disappearance of the tracer from the alveolar saline and its appearance in the arterial blood during a 1-h period. CLSE treatment was associated with significantly increased 72-h survival in hyperoxia compared with saline-treated controls (number of survivors: 16/17 vs. 5/11, P less than 0.01). CLSE treatment significantly reduced the rate constant for the movement of cyanocobalamin out of the alveolar space (24 +/- 5 vs. 42 +/- 6 min-1 x 10(-3), P less than 0.01) and tracer appearance in the blood at the end of the study (7 +/- 1 vs. 34 +/- 13%, P less than 0.01) when compared with values in saline controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2793671     DOI: 10.1152/jappl.1989.67.2.688

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

Review 1.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

Review 2.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties.

Authors:  N Gilliard; G P Heldt; J Loredo; H Gasser; H Redl; T A Merritt; R G Spragg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 4.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

6.  Spatial and temporal expression of surfactant proteins in hyperoxia-induced neonatal rat lung injury.

Authors:  Simone A J ter Horst; Margot Fijlstra; Sujata Sengupta; Frans J Walther; Gerry T M Wagenaar
Journal:  BMC Pulm Med       Date:  2006-04-18       Impact factor: 3.317

Review 7.  Pediatric Acute Respiratory Distress Syndrome: Fibrosis versus Repair.

Authors:  Daniel Im; Wei Shi; Barbara Driscoll
Journal:  Front Pediatr       Date:  2016-03-30       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.